PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.

Urology
EAU PSMA prostate cancer prostate specific membrane antigen risk score

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
01 2022
Historique:
received: 02 07 2021
revised: 25 09 2021
pubmed: 9 10 2021
medline: 19 2 2022
entrez: 8 10 2021
Statut: ppublish

Résumé

The European Association of Urology (EAU) prostate cancer guidelines panel recommends risk groups for biochemical recurrence (BCR) of prostate cancer to identify men at high risk of progression or metastatic disease. The rapidly growing availability of PSMA-directed PET imaging will impact prostate cancer staging. We determined the rates of local and metastatic disease in BCR and biochemical persistence (BCP) of prostate cancer stratified by EAU BCR risk groups and BCP.

Identifiants

DOI: 10.2967/jnumed.121.262821 PMID: 34620731 PMC: PMC8717195
pubmed: 34620731
pii: jnumed.121.262821
doi: 10.2967/jnumed.121.262821
pmc: PMC8717195
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

76-80

Subventions

Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235741
Pays : United States

Informations de copyright

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Eur Urol. 2019 Jun;75(6):896-900
pubmed: 30955970
J Nucl Med. 2020 Jun;61(6):866-872
pubmed: 31676727
Eur Urol. 2018 Mar;73(3):436-444
pubmed: 28779974
Prostate. 2018 Jun;78(9):676-681
pubmed: 29570821
J Nucl Med. 2021 Jul 29;:
pubmed: 34326128
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
J Urol. 2021 Jul;206(1):52-61
pubmed: 33634707
Eur Urol Focus. 2020 Mar 15;6(2):231-234
pubmed: 31248850
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
J Nucl Med. 2020 Dec;61(12):1793-1799
pubmed: 32358094
J Urol. 2019 Dec;202(6):1174-1181
pubmed: 31233369
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
J Nucl Med. 2021 Feb;62(2):146-148
pubmed: 33468543
Eur Urol Focus. 2021 Mar;7(2):238-240
pubmed: 33386288

Auteurs

Justin Ferdinandus (J)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany; wolfgang.fendler@uk-essen.de.
Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Andrea Farolfi (A)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Samuel Washington (S)

Department of Urology, University of California San Francisco, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

Osama Mohamad (O)

Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Miguel H Pampaloni (MH)

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.

Peter J H Scott (PJH)

Department of Radiology, University of Michigan, Ann Arbor, Michigan; and.

Melissa Rodnick (M)

Department of Radiology, University of Michigan, Ann Arbor, Michigan; and.

Benjamin L Viglianti (BL)

Department of Radiology, University of Michigan, Ann Arbor, Michigan; and.

Matthias Eiber (M)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Johannes Czernin (J)

Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Wesley R Armstrong (WR)

Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Jeremie Calais (J)

Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.

Morand Piert (M)

Department of Radiology, University of Michigan, Ann Arbor, Michigan; and.

Articles similaires

Actual clinical practice pattern in SWL after COVID-19 era: a critical evaluation from different aspects.

Erhan Erdoğan, Göksu Sarıca, Cahit Şahin et al.
1.00
Humans COVID-19 Lithotripsy Practice Patterns, Physicians' SARS-CoV-2

Battle of the bots: a comparative analysis of ChatGPT and bing AI for kidney stone-related questions.

Amber K McMahon, Russell S Terry, Willian E Ito et al.
1.00
Humans Kidney Calculi Practice Guidelines as Topic Surveys and Questionnaires Guideline Adherence

The impact of single-port robotic surgery: a survey among urology residents and fellows in the United States.

Eugenio Bologna, Leslie Claire Licari, Ketan K Badani et al.
1.00
Robotic Surgical Procedures Internship and Residency United States Humans Surveys and Questionnaires

Trends of European School of Urology (ESU) training and resident education: an overview of 2 decades of EAU education programme.

Bhaskar Somani, Juan Gomez-Rivas, Tiago Ribeiro de Oliveira et al.
1.00
Urology Europe Humans Internship and Residency Female

Classifications MeSH

questionsmedicales.fr › Professions de santé › Médecine › Spécialités chirurgicales › Urologie › PSMA PET Validates Higher Rates of Metastatic...